ABSTRACT
Studies were carried out on the combination of Cimetidine (CMTD) with Cytoxan (CTX) in three murine tumors. While the combination significantly potentiated the anticancer effect of CTX in L1210 leukemia, the results with P388 leukemia were not significantly different. The results with Lewis Lung Carcinoma showed a consistent reduction in the number of metastases. However, there was no consistent concomitant prolongation in survival. The host strain, biology of the tumour and the drug used in combination with CMTD might be some of the factors responsible for the varied response.
Subject(s)
Cimetidine/administration & dosage , Cyclophosphamide/administration & dosage , Leukemia L1210/drug therapy , Leukemia P388/drug therapy , Leukemia, Experimental/drug therapy , Animals , Cimetidine/therapeutic use , Cyclophosphamide/therapeutic use , Drug Therapy, Combination , Female , Lung Neoplasms/drug therapy , Male , Mice , Mice, Inbred DBA , Neoplasm TransplantationABSTRACT
A comparative study of cytostatic combinations was carried out in early and advanced murine leukaemia P388 by using the new protein synthesis inhibitor bouvardin (BVD) along with the known anticancer drugs vincristine (VCR) and cis-diamminedichloroplatinum (DDP). The results indicate that the combination of BVD with DDP enhances the antineoplastic activity in comparison with single-agent therapy in early leukaemia. However, BVD could not indicate its superiority by way of tumour cell killing in three drug combinations, when administered with VCR and/or DDP, against advanced leukaemia.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia P388/drug therapy , Leukemia, Experimental/drug therapy , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Cisplatin/therapeutic use , Female , Male , Mice , Peptides, Cyclic/therapeutic use , Time Factors , Vincristine/therapeutic useABSTRACT
The ability of Amphotericin B ('Fungizone') to alter the natural resistance of leukemia L1210 to vincristine was studied in BDF1 mice Neither Fungizone nor the "solubilizing agent" sodium deoxycholate, when used in combination with vincristine potentiated the activity of the drug against L1210. There was no change in the activity pattern of 5-fluorouracil against L1210 or vincristine against P388 lymphocytic leukemia respectively, which are sensitive to these drugs. Thus, both Fungizone and sodium deoxycholate failed to improve the activity of the drugs in either a naturally resistant or sensitive murine leukemia in vivo.
Subject(s)
Amphotericin B/administration & dosage , Antineoplastic Combined Chemotherapy Protocols , Deoxycholic Acid/administration & dosage , Leukemia, Experimental/drug therapy , Animals , Drug Administration Schedule , Drug Resistance , Drug Synergism , Fluorouracil/administration & dosage , Leukemia L1210/drug therapy , Leukemia P388/drug therapy , Mice , Mice, Inbred DBA , Neoplasm Transplantation , Vincristine/administration & dosageABSTRACT
A new anti-cancer drug, code named GCE pending chemical characterization, has been isolated from a plant Gymnosporia rothiana, Laws. In addition to exhibiting good anti-cancer activities, GCE prolongs the "S" phase of cell cycle. This property has been exploited in evolving a new combination chemotherapy schedule with "S" phase sensitive drugs. Cures in L1210 bearing mice have been observed by administering GCE 2 hours prior to administration of "S" phase sensitive drug such as cytosine arabinoside (Ara-C), hydroxyurea (HU) or 5 fluorouracil (5FU).
